Leo I. Gordon, MD, on Hodgkin Lymphoma: Management Strategies

2017 NCCN Annual Conference

Leo I. Gordon, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses novel immunomodulatory agents and standard treatment options for patients with relapsed or refractory Hodgkin lymphoma.

Christina S. Chu, MD, on HPV and Cervical/Vulvar Cancer

Christina S. Chu, MD, of Fox Chase Cancer Cen...

Pancreatic Cancer

Margaret A. Tempero, MD, on Pancreatic Cancer: Active Systemic Treatment

Margaret A. Tempero, MD, of the UCSF Helen Di...

Sarcoma

Suzanne George, MD, on Soft-Tissue Sarcoma: Evolving Treatment

Suzanne George, MD, of Dana-Farber Cancer Ins...

Issues in Oncology

Paul M. Cinciripini, PhD, on Smoking Cessation in Patients With Cancer

Paul M. Cinciripini, PhD, of The University o...

Head and Neck Cancer

David G. Pfister, MD, on HPV and Head and Neck Cancer

David G. Pfister, MD, of Memorial Sloan Kette...

Jan

Today In Oncology

Leo I. Gordon, MD, on Hodgkin Lymphoma: Management Strategies

Related Videos

Christina S. Chu, MD, on HPV and Cervical/Vulvar Cancer

Margaret A. Tempero, MD, on Pancreatic Cancer: Active Systemic Treatment

Suzanne George, MD, on Soft-Tissue Sarcoma: Evolving Treatment

Paul M. Cinciripini, PhD, on Smoking Cessation in Patients With Cancer

David G. Pfister, MD, on HPV and Head and Neck Cancer

New Study Finds Suspicious Lesions on Breast MRI in Neoadjuvant Setting Are Unlikely to Be Malignant

IMpower133 Update Atezolizumab Plus Carboplatin/Etoposide for Extensive-Stage Small Cell Lung Cancer

Multiancestry Meta-analysis of Prostate Cancer Genetics

Final Overall Survival Results of the IDEA Collaboration 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon Cancer

Integrated Palliative and Oncology Care for Patients Receiving Treatment for Acute Myeloid Leukemia